Syndax Pharmaceuticals Stock Alpha and Beta Analysis
| SNDX Stock | USD 16.73 0.64 3.98% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Syndax Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Syndax Pharmaceuticals over a specified time horizon. Remember, high Syndax Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Syndax Pharmaceuticals' market risk premium analysis include:
Beta 2.39 | Alpha (0.56) | Risk 4.18 | Sharpe Ratio (0.06) | Expected Return (0.24) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Syndax |
Syndax Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Syndax Pharmaceuticals market risk premium is the additional return an investor will receive from holding Syndax Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Syndax Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Syndax Pharmaceuticals' performance over market.| α | -0.56 | β | 2.39 |
Syndax Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Syndax Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Syndax Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Syndax Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Syndax Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Syndax Pharmaceuticals shares will generate the highest return on investment. By understating and applying Syndax Pharmaceuticals stock market price indicators, traders can identify Syndax Pharmaceuticals position entry and exit signals to maximize returns.
Syndax Pharmaceuticals Return and Market Media
The median price of Syndax Pharmaceuticals for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 18.94 with a coefficient of variation of 7.77. The daily time series for the period is distributed with a sample standard deviation of 1.47, arithmetic mean of 18.88, and mean deviation of 1.09. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 | 09/06/2024 |
2 | Acquisition by Gallagher Neil of 69375 shares of Syndax Pharmaceuticals at 22.28 subject to Rule 16b-3 | 09/23/2024 |
3 | Syndax Announces Participation in November Investor Conferences | 11/01/2024 |
4 | Syndax Pharmaceuticals, Inc. Q3 2024 Earnings Call Transcript | 11/07/2024 |
5 | Analysts Are Updating Their Syndax Pharmaceuticals, Inc. Estimates After Its Third-Quarter Results | 11/08/2024 |
6 | Syndax stock falls after leukemia drug data | 11/12/2024 |
7 | Scotiabank cuts SNDX stock target, keeps rating on FDA approval risk | 11/13/2024 |
8 | Simplify Asset Management Inc. Has 2.35 Million Position in Syndax Pharmaceuticals, Inc. | 11/15/2024 |
9 | STAT Syndax wins U.S. approval for leukemia treatment | 11/18/2024 |
10 | Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Revuforj | 11/20/2024 |
11 | Syndax Pharmaceuticals Stock Price Expected to Rise, Citigroup Analyst Says | 11/22/2024 |
About Syndax Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Syndax or other stocks. Alpha measures the amount that position in Syndax Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.0223 | 0.0198 | Price To Sales Ratio | 7.34 | 6.97 |
Syndax Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Syndax Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Syndax Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Syndax Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Syndax Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Syndax Pharmaceuticals' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Syndax Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.